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Inducible nitric oxide synthase (iNOS) and cyclooxygenase-
2 (COX-2) are frequently overexpressed in tumor tissues or
transformed cells. In the present work, we assessed the
effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) on
expression of iNOS and COX-2 in mouse skin. Topical
application to the dorsal skin of female ICR mice of
10 nmol TPA led to maximal induction of iNOS and COX-2
protein expression at ~2 and 4 h, respectively. When
applied topically onto shaven backs of mice 30 min prior
to TPA, the NOS inhibitor aminoguanidine (AG) inhibited
the expression of COX-2 protein at the pharmacologically
effective dose. Pretreatment with a more specific iNOS
inhibitor, NG-nitro-l-arginine-methyl ester, also sup-
pressed TPA-induced COX-2 expression. Immunohisto-
chemical analysis of TPA-treated mouse skin using an
anti-nitrotyrosine antibody reveals enhanced levels of
nitrotyrosine protein localized in epidermal and dermal
layers. Topical application of NO donors, such as sodium
nitroprusside (SNP) and S-nitroso-N-acetyl-d,l-penicilla-
mine, induced expression of COX-2 in mouse skin, which
was attenuated by the NO scavenger 2-(4-carboxyphenyl)-
4,4,5,5-tetramethyl imidazoline-1-oxyl 3-oxide. SNP treat-
ment stimulated NF-kB activation in mouse skin, which
was associated with the degradation of IkBa. Topical appli-
cation of inhibitors of NF-kB, such as pyrrolidine dithio-
carbamate or N-a-p-tosyl-l-lysine chloromethylketone,
inhibited the SNP-induced COX-2 expression. SNP
induced a weak but concentration-related increase in
COX-2 expression in cultured mouse keratinocytes, which
was abolished by treatment with SN50, a specific inhibitor
of nuclear translocation of NF-kB. Mouse keratinocytes
treated with SNP exhibited an elevated NF-kB-driven
COX-2 promoter activity. Topical application of AG
(10 mmol) prior to each TPA treatment after initiation
reduced the multiplicity of papillomas by 44% at 22 weeks.
In conclusion, up-regulation of COX-2 by NO may be
mediated by activation of NF-kB in mouse skin, which
provides a molecular mechanism by which COX-2 is
induced during tumor promotion.
Introduction
Nitric oxide (NO) plays a major role in regulating vascular
tone, neurotransmission, platelet aggregation and other
homeostatic mechanisms (1). NO is produced endogenously
during arginine metabolism by different isoforms of nitric
oxide synthase (NOS) (2). Elevated levels of NO have
been detected in a variety of pathophysiological processes,
including circulatory shock (3), inflammation (4) and carcino-
genesis (5). Molecular cloning and sequencing analyses
revealed the existence of at least three main types of NOS.
Both neuronal NOS and endothelial NOS are constitutively
expressed (6), whereas inducible NOS (iNOS) is expressed
in response to interferon-g, lipopolysaccharide (LPS) and
a variety of proinflammatory cytokines (3). iNOS is respon-
sible for the overproduction of NO which is often obser-
ved during inflammation (4) and tumor development (7).
Increased iNOS expression and activity were reported in
human gynecological (8), breast (9) and central nervous
system (10) tumors.
Cyclooxygenase (COX), an important enzyme involved in
mediating the inflammatory process, catalyzes the rate-limit-
ing step in the synthesis of prostaglandins from arachidonic
acid. There are two isoforms of COX, designated COX-1 and
COX-2 (11). COX-1 is expressed constitutively in most tissues
and appears to be responsible for maintaining normal physio-
logical functions. In contrast, COX-2 is detectable in only
certain types of tissues and is induced transiently by growth
factors, proinflammatory cytokines, tumor promoters and
bacterial toxins (12,13). Like iNOS, expression of COX-2
has been frequently increased in several types of malignancies
(14--18).
Several studies have suggested an important link between
the iNOS and COX pathways, although the precise mechanism
underlying such interaction remains poorly understood (19).
Conflicting data present in the literature have described both
an inhibitory and stimulatory effects of NO on COX expres-
sion either in vitro or in vivo (19--21). Stimulation of a wide
variety of cell types, including endothelial cells, with cyto-
kines and other agents results in up-regulation of COX-2 and
this is often accompanied by an increase in iNOS levels
(22,23). Whether the increase in iNOS expression occurs
before that of COX-2 is uncertain and it is possible that
regulation of each enzyme may be cell type specific. For
example, NO stimulates COX activity in both the
LPS-activated murine macrophage cell line RAW 264.7 and
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fibroblasts (24), but inhibits the production of PGE2 in rat
Kupffer cells (25) and in cultured bovine endothelial cells
(26). The reason for such a discrepancy is unknown. Studies
in rat mesangial and human lung epithelial cells suggest that
NO may directly interact with COX-2 at the transcriptional
level and that this effect is mediated through a cGMP-depen-
dent mechanism (27,28). Regulation of COX-2 gene expres-
sion by NO has also been suggested to occur post-
transcriptionally in rat osteoblasts (29).
In the present study, we have found that the tumor promoter
12-O-tetradecanoylphorbol-13-acetate (TPA) induces both
iNOS and COX-2 expression in mouse skin in vivo. We
hypothesize that NO could up-regulate COX-2 in TPA-
stimulated mouse skin. In order to test this possibility, we
utilized iNOS inhibitors and also NO releasing compounds,
examining whether they can modulate COX-2 expression
when topically applied to mouse skin.
Materials and methods
Chemicals
7,12-Dimethylbenz[a]anthracene (DMBA), sodium nitroprusside (SNP),
S-nitroso-N-acetyl-d,l-penicillamine (SNAP), aminoguanidine (AG), pyrroli-
dine dithiocarbamate (PDTC) and N-a-p-tosyl-l-lysine chloromethylketone
(TPCK) were purchased from Sigma-Aldrich (St Louis, MO). NG-nitro-
l-arginine-methyl ester (NAME) was purchased from Research Biochemicals
International (RBI) (Natick, MA). SN50 and its mutated form (SN50M) were
purchased from BIOMOL Research Laboratories Inc. (Plymouth Meeting,
PA). TPA and 2-(4-carboxyphenyl)-4,4,5,5-tetramethyl imidazoline-1-oxyl
3-oxide (carboxy-PTIO) were obtained from Alexis Biochemicals (San
Diego, CA). A COX-2 promoter construct and a pELAM-Luc construct con-
taining the NF-kB sites were generous gifts from Dr Y.-J.Bang (College of
Medicine, Seoul National University, Seoul, South Korea) and Dr Youngmi
Kim (University of Ulsan School of Medicine, Seoul, Korea), respectively. All
other chemicals used were in the purest form available commercially.
Animal treatment
Female ICR mice (6--7 weeks of age) were supplied from the Dae-Han Biolink
Ltd Experimental Animal Center (Daejeon, Korea). The animals were housed
in climate controlled quarters (24  1C at 50% humidity) with a 12 h light/
12 h dark cycle. The dorsal side of the skin was shaved using an electric clipper
and only those animals in the resting phase of the hair cycle were used in all
experiments. TPA and SNP were dissolved in 200 ml of acetone and applied to
the dorsal shaven area.
Western blot analysis
The mice were topically treated on their shaven backs with the indicated doses
of SNP or TPA and were killed by cervical dislocation at the indicated times.
For isolation of protein from mouse skin, the dorsal skin was excised and the
fat was removed on ice, immediately placed in liquid nitrogen and pulverized
in mortar. The pulverized skin was homogenized on ice for 20 s with a Polytron
tissue homogenizer and lysed in 2 ml ice-cold lysis buffer [20 mM Tris--HCl
(pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100,
2.5 mM sodium pyrophosphate, 1 mM glycerolphosphate, 1 mM Na3VO4,
1 g/ml leupeptin] for 10 min. Lysates were centrifuged at 12 000 g for 20 min
and supernatant containing 30 mg protein was boiled in SDS sample loading
buffer for 10 min before electrophoresis on a 12% SDS--polyacrylamide gel.
After electrophoresis for 2 h, proteins in the SDS--polyacrylamide gel were
transferred to PVDF membrane (Gelman Laboratory, Ann Arbor, MI) and the
blots were blocked with 5% non-fat dry milk in PBST buffer [phosphate-
buffered saline (PBS) containing 0.1% Tween-20] for 60 min at room temp-
erature. The membranes were incubated for 2 h at room temperature with a
1:1000 dilution of COX-2, iNOS and IkBa polyclonal antibodies (Santa Cruz
Biotechnology, Santa Cruz, CA). Equal lane loading was assessed using actin
(Sigma Chemical Co., St Louis, MO). The blots were rinsed three times with
PBST for 5 min each. Washed blots were incubated with a 1:5000 dilution of
horseradish peroxidase conjugated-secondary antibody (Zymed Laboratories,
San Francisco, CA) and then washed again three times with PBST. The
transferred proteins were visualized with an enhanced chemiluminescence
detection kit (Amersham Pharmacia Biotech, Little Chalfont, UK).
Immunohistochemical staining of protein nitrotyrosine and COX-2
Sections (4 mm) of formalin-fixed, paraffin-embedded tissue were cut onto
silanized glass slides and deparaffinized three times with xylene for 10 min
each and rehydrated through a graded alcohol bath. The deparaffinized sec-
tions were heated and boiled twice for 6 min in 10 mM citrate buffer, pH 6.0,
for antigen retrieval. To diminish non-specific staining, each section was
treated with 3% hydrogen peroxide in methanol for 15 min. For the detection
of nitrotyrosine and COX-2, slides were incubated with 1:50--100 dilutions of a
polyclonal anti-nitrotyrosine antibody (Cell Signaling Technology, Beverly,
MA) or monoclonal anti-COX-2 antibody (Cayman Chemical, Ann Arbor, MI)
at room temperature for 60 min in Tris-buffered saline TBS containing
0.05% Tween-20 and then developed using the HPR EnVisionTM System
(Dako, Glostrup, Denmark). The peroxidase-binding sites were detected by
staining with 3,30-diaminobenzidine tetrahydrochloride (Dako). Finally, coun-
terstaining was performed using Mayer's hematoxylin.
Nitrite assay
The female ICR mice were treated topically with 10 nmol TPA. Mice were
killed by cervical dislocation and the skin was excised, minced and homo-
genized in 50 mM potassium phosphate buffer (pH 7.2). The homogenates
were centrifuged at 25 000 g for 20 min at 4C. The amount of nitrite, an
indicator of NO synthesis, was measured by use of the Griess reaction (30).
Tissue supernatants (150 ml) were added 150 ml of the Griess reagent (1%
sulphanilamide, 0.1% naphthylethylenediamine, 2.5% phosphoric acid) in
duplicate on 96-well plates. After incubation at room temperature for 10 min,
absorbance at 570 nm was measured with a Spectrafluor ELISA reader (Tecan
US, Durham, NC).
Measurement of prostaglandin E2 (PGE2)
Mice were topically treated on their shaven backs with TPA or SNP and killed
by cervical dislocation at the indicated times. The pulverized skin was homo-
genized with ice-cold ethanol and centrifuged for 10 min at 3000 g. The
supernatant was diluted to 15% with respect to ethanol by adding 0.1 M sodium
formate and pelleted protein was dissolved in 8 M urea. The diluted super-
natant was applied to a preactivated AmprepTM C-18 reverse phase cartridge
(Amersham Pharmacia Biotech) and eicosanoids were released with ethyl
acetate containing 1% methanol. The extract was evaporated to dryness
under a stream of nitrogen and resuspended in enzyme immunoassay buffer.
The amounts of PGE2 were measured using a PGE2 enzyme immunoassay kit
(Amersham Pharmacia Biotech) according to the manufacturer's protocol. The
quantity of dissolved protein was determined by the BCA method.
Preparation of nuclear extracts
The nuclear extract from mouse skin was prepared as described previously
(31). Briefly, scraped dorsal skin of mice was homogenized in 1 ml of ice-cold
hypotonic buffer A [10 mM HEPES (pH 7.8), 10 mM KCl, 2 mM MgCl2, 1 mM
DTT, 0.1 mM EDTA, 0.1 mM phenylmethylsulfonyl fluoride (PMSF)]. After
15 min incubation on ice, the nucleoprotein complexes were lysed with 125 ml
of 10% Nonidet P-40 (NP-40) solution, followed by centrifugation for 2 min at
14 800 g. The nuclei were washed once with 400 ml of buffer A plus 25 ml of
10% NP-40, centrifuged, resuspended in 150 ml of buffer C [50 mM HEPES
(pH 7.8), 50 mM KCl, 300 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 0.1 mM
PMSF and 20% glycerol] and centrifuged for 5 min at 14 800 g. The super-
natant containing nuclear proteins was collected and stored at ÿ70C after
determination of protein concentrations.
Electrophoretic mobility shift assay (EMSA)
EMSA was performed using a DNA--protein binding detection kit (Gibco
BRL, Grand Island, NY) according to the manufacturer's protocol. Briefly,
the NF-kB oligonucleotide probe (50-AGT TGA GGG GAC TTT CCC AGG
C-30) was labeled with [g-32P]ATP by T4 polynucleotide kinase and purified
on a Nick column (Amersham Pharmacia Biotech). The binding reaction was
carried out in a total volume of 25 ml containing 10 mM Tris--HCl (pH 7.5),
100 mM NaCl, 1 mM DTT, 1 mM EDTA, 4% (v/v) glycerol, 0.1 mg/ml
sonicated salmon sperm DNA, 10 mg nuclear extract and 100 000 c.p.m. of
labeled probe. After 50 min incubation at room temperature, 2 ml of 0.1%
bromophenol blue was added and samples were electrophoresed through a 6%
non-denaturating polyacrylamide gel at 150 V for 2 h. Finally, the gel was
dried and exposed to X-ray film.
Two-stage mouse skin carcinogenesis
Groups of 25--30 female ICR mice were treated on their shaven backs with a
single topical dose of DMBA (0.2 mmol) in 0.2 ml acetone:DMSO (85:15 v/v)
or the same volume of solvent alone. One week after initiation, 10 nmol of
TPA in 0.2 ml acetone was topically applied twice a week until termination of
the experiment. AG dissolved in 0.2 ml acetone:DMSO (85:15) was topically
applied 30 min before each TPA treatment. Control animals were pretreated
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with vehicle alone. Starting 1 week following promoter treatment, tumors of at
least 1 mm diameter were counted every other week.
Cell culture and preparation of cell lysates for western blot analysis
The spontaneously transformed murine keratinocyte cell line Pam212, kindly
donated by Dr T.-Y.Kim (Catholic University School of Medicine, Seoul,
South Korea), was maintained in DMEM (Hyclone, Rogan, UT) supplemented
with 10% fetal bovine serum (Gibco BRL) and antibiotics (100 U/ml penicillin
and 100 U/ml streptomycin) at 37C in 5% CO2. For stimulation, 1.5  106
Pam212 cells were seeded in 6-well dishes in 2 ml of medium. After incubation
for 24 h, the cells were exposed to SNP (0.25 mM) with or without SN50
pretreatment and incubated for an additional 24 h. Subsequently, the medium
was aspirated and the cells were washed twice with ice-cold PBS. The cells
were lysed by scraping them off into 80 ml of ice-cold lysis buffer [20 mM
Tris--HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-
100, 2.5 mM sodium pyrophosphate, 1 mM glycerolphosphate, 1 mM Na3VO4
and 1 mg/ml leupeptin]. The insoluble material was pelleted by centrifugation
(12 000 g) for 15 min at 4C. The supernatant was removed, divided into
aliquots, quickly frozen in liquid nitrogen and stored at ÿ80C. The protein
concentration of the keratinocyte lysate was determined using the BCA protein
assay kit (Pierce, Rockford, IL).
Transient transfection and luciferase reporter assays in Pam212 keratinocytes
Pam212 keratinocytes were seeded at a density of 1 105 cells in 6-well plates
and grown to 60--70% confluence in complete growth medium containing 10%
fetal bovine serum. For each triplicate of samples, 2.5 mg luciferase reporter
plasmid construct harboring the NF-kB-binding site and 0.5 mg pCMV-
b-galactosidase control vector were co-transfected using DOTAP liposomal
transfection reagent (Roche Molecular Biochemicals, Mannheim, Germany)
according to the manufacturer's protocol. After 18 h, the medium was changed
and the cells were stimulated with SNP and other stimuli. After 6 h incubation,
the cells were washed twice with PBS, lysed in 1 reporter lysis buffer
(Promega, Madison, WI). Luciferase activity was measured using the Lucifer-
ase Assay System (Promega) and expressed as relative luciferase activity 
SD, which was corrected for transfection efficiency based on the b-galactosi-
dase activity.
Results
Effects of TPA on iNOS and COX-2 expression in mouse skin
When 10 nmol of TPA was applied topically to the shaven
backs of female ICR mice, the iNOS protein level increased
transiently, with maximal expression observed at 2 h
(Figure 1A). Under the same experimental conditions, COX-
2 expression was apparently induced 4 h after TPA application
(Figure 1A), indicating that iNOS induction may occur before
that of COX-2. This finding suggests that expression of COX-2
might be regulated by NO in mouse skin. To confirm the
formation of NO in TPA-stimulated mouse skin, we conducted
immunohistochemical analysis with 3-nitrotyrosine antibody.
In acetone-treated control skin, specific 3-nitrotyrosine immu-
nostaining was barely detectable in the dorsal layer. Upon treat-
ment with TPA for 4 h, however, expression of protein
nitrotyrosine increased inadose-dependentmanner (Figure 1B).
Effects of AG on TPA-induced NO production and COX-2
expression in mouse skin
In order to examine whether NO can activate COX-2 expres-
sion in TPA-treated mouse skin, we have topically applied the
selective iNOS inhibitor AG 30 min prior to TPA treatment.
We first tried to ensure that AG could inhibit iNOS in mouse
skin after topical application. Pretreatment with this iNOS
inhibitor decreased the TPA-induced NO production in
mouse skin (Figure 2A). AG suppressed the expression of
COX-2 protein induced by TPA at the pharmacologically
effective dose (i.e. 30 mmol) capable of inhibiting iNOS
activity (Figure 2B). Inhibition of TPA-induced COX-2
expression was also attained with another iNOS inhibitor,
NAME (Figure 2C).
Effects of SNP on PGE2 production and COX-2 expression in
mouse skin
In order to verify whether NO produced by TPA can induce
COX-2 expression in mouse skin, we next sought to determine
the effect of exogenously applied NO on COX-2 expression. In
this experiment, dorsal skin of mice was treated with two dif-
ferent NO donors, SNP and SNAP. As illustrated in Figure 3A,
topical treatment of female ICR mice with 2 or 20 mmol SNP
significantly increased PGE2 synthesis. In addition, SNP treat-
ment resulted in marked induction of COX-2 expression in
a dose-dependent manner (Figure 3B). Another NO donor,
SNAP also increased expression of COX-2 when topically
applied onto mouse skin (Figure 3C). Furthermore, topical
application of carboxy-PTIO, a known NO scavenger, 15 min
before SNP treatment abolished COX-2 expression in
Fig. 1. TPA-induced expression of iNOS and COX-2 protein (A) and protein
nitrotyrosine (B) in mouse skin. (A) Dorsal skins of female ICR mice were
treated topically with acetone alone or with 10 nmol TPA in acetone for the
indicated time periods. Protein extracts (30 mg) were loaded onto a 12%
SDS--polyacrylamide gel, electrophoresed and subsequently transferred onto
PVDF membrane. Other experimental details are described in Materials and
methods. Immunoblots were probed with an iNOS or COX-2 polyclonal
antibody. (B) Paraffin-embedded tissues from TPA-treated mice were
immunostained for protein nitrotyrosine and counterstained with
hematoxylin, as described in Materials and methods. Protein nitrotyrosine
staining gives a brown reaction product. (a) Acetone-treated control skin.
(b) TPA (10 nmol)-treated mouse skin. (c) TPA (100 nmol)-treated mouse
skin. A color version is available as supplementary material online.
NO-induced COX-2 expression in mouse skin
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SNP-treated mouse skin (Figure 3D). To assess the localiza-
tion of COX-2 by SNP in mouse skin, we conducted an
immunohistochemical analysis. In acetone-treated control
skin, specific COX-2 immunostaining was detectable in the
dermal sebaceous gland (Figure 4A). In contrast, expression of
COX-2 increased dramatically in the epidermal basal layer
upon treatment with 20 mmol SNP for 2 h (Figure 4B).
Induction of NF-kB DNA binding activity by SNP
Because NF-kB is known to play a crucial role in regulating
the induction of COX-2, we have determined whether SNP
could activate this transcription factor in nuclear extracts
obtained from mouse skin. Effects of SNP on NF-kB activa-
tion were examined by gel shift assay using an oligonucleotide
harboring an NF-kB consensus sequence. SNP treatment caused
activation of NF-kB in terms of its DNA binding (Figure 5A).
One of the most critical steps in NF-kB activation is dis-
sociation of the NF-kB subunits from IkB, which is mediated
through phosphorylation and subsequent proteolytic degrada-
tion of the inhibitory subunit. To determine whether the
increased NF-kB DNA binding induced by SNP was mediated
through its induction of IkBa degradation, the cytoplasmic
level of IkBa was determined by western blot analysis. As
illustrated in Figure 5B, topical application of SNP led to
degradation of IkBa by as early as 30 min. To better assess
the role of NF-kB in the induction of COX-2 expression in
mouse skin, we have investigated the effect of PDTC and
TPCK, known inhibitors of NF-kB, on SNP-induced COX-2
expression. Topical application of PDTC or TPCK at a dose
capable of inactivating NF-kB suppressed the induction of
COX-2 expression by SNP (Figure 5C).
Induction of COX-2 and NF-kB transcriptional activity by
SNP in murine keratinocytes
We also confirmed the capability of SNP to induce COX-2
expression using cultured keratinocytes. Thus, Pam212 cells
treated with varying amounts of SNP (0.05--0.5 mM) displayed
a concentration-dependent increase in COX-2 protein levels
(Figure 6A). To verify the role of NF-kB in SNP-mediated
COX-2 induction, we utilized a specific NF-kB inhibitor,
SN50, that blocks the nuclear translocation of NF-kB. As
illustrated in Figure 6B, SN50 inhibited COX-2 expression in
Pam212 cells treated with SNP. However, the same concentra-
tion of the inactive peptide SN50M with a mutated sequence
failed to inhibit SNP-induced COX-2 expression (Figure 6B).
In another experiment, we demonstrated that SNP enhanced
COX-2 promoter activity, as determined by the luciferase
reporter gene assay (Figure 6C). To determine a potential
effect of SNP on the transcriptional activity of NF-kB,
Pam212 cells were transiently transfected with a luciferase
reporter construct containing a NF-kB site. SNP (0.5 mM)
activated the transcriptional activity of NF-kB (Figure 6D).
Likewise, LPS and tumor necrosis factor a, which are well-
known inducers of COX-2, activated the transcriptional activ-
ity of NF-kB in Pam212 cells (data not shown). Based on these
findings, it is conceivable that SNP-induced COX-2 expres-
sion is regulated, at least in part, by NF-kB in murine kerati-
nocytes as well as in mouse skin in vivo.
Inhibitory effect of AG on TPA-induced mouse skin tumor
promotion
Up-regulation of iNOS and production of NO occur in many
pathological conditions, including tumorigenesis. To examine
whether NO is involved in mouse skin tumor promotion, dorsal
skin of mice was subjected to topical application of AG prior to
TPA, following initiation with DMBA. Papillomas were first
observed in the DMBA  TPA group after 8 weeks of promo-
tion and reached 100% incidence with ~16 papillomas/mouse
at week 22 (Figure 7). AG at 10 mmol significantly lowered
the multiplicity of papillomas while it did not much influence
the tumor incidence.
Fig. 2. Inhibitory effects of AG on phorbol ester-induced nitrite production
(A) and COX-2 expression (B and C). (A) Female ICR mice were treated
topically with 0.2 ml acetone or aminoguanidine (30 mmol) in the same
volume of acetone 30 min prior to 10 nmol TPA and animals were killed 4 h
after the TPA treatment. The amount of nitrite produced was determined by
the Griess reaction. Data are expressed as mean  SD (n  6). Significantly
different from the TPA alone group (P 5 0.05). (B) Protein was analyzed
for COX-2 by immunoblotting. The western blot is representative of three
independent experiments which produced similar results. Quantification of
COX-2 expression was normalized to actin using a densitometer. (C) Female
ICR mice were treated topically with acetone or with 10 mmol NAME 30 min
prior to 10 nmol TPA. Animals were killed by cervical dislocation 4 h
later. Expression of COX-2 was measured by western blot analysis.
K.-S.Chun et al.
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Discussion
Recent studies suggest that iNOS may play a role in tumor
development. Increased iNOS expression and/or activity
was observed in diverse human tumors (8--10). In addition,
enhanced nitrotyrosine accumulation in inflammed mucosa
of patients with ulcerative colitis and gastritis implies produc-
tion of NO and its possible involvement in the pathogenesis of
these diseases (5). Rao et al. (32) and Takahashi et al. (33)
have demonstrated that azoxymethane-induced colon tumors
exhibit elevated expression and activity of iNOS compared
with adjacent normal colonic tissue. Furthermore, iNOS selec-
tive inhibitors, such as S,S0-1,4-phenylene-bis(1,2-ethanediyl)-
bis-isothiourea and NAME, attenuated azoxymethane-induced
aberrant crypt focus formation in rats (7,34). In line with this
notion, we found that the iNOS inhibitor AG at 10 mmol
Fig. 3. Effect of SNP on PGE2 production and COX-2 protein expression in mouse skin. (A) Female ICR mice were treated topically with 2 or 20 mmol SNP and
animals were killed 2 h after the SNP treatment. Data are expressed as means SD obtained from 5 mice/group.  ,Significantly different from the group treated
with control (P 5 0.005; P 5 0.001). (B) Mice were treated topically with the indicated doses of SNP. Animals were killed by cervical dislocation 2 h
later. The western blot assay was conducted as described in the legend to Figure 1. (C) Mice were treated topically with SNAP (2 or 5 mmol) and killed by cervical
dislocation 2 h later. (D) Mice were treated topically with either the solvent alone or carboxy-PTIO (2 mmol) 15 min prior to 20 mmol SNP treatment.
Animals were killed by cervical dislocation 2 h later. Quantification of COX-2 expression was normalized to actin using a densitometer. Values are means  SD
of three independent experiments. Significantly different from the group treated with control (P 5 0.05).
NO-induced COX-2 expression in mouse skin
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significantly lowered the multiplicity of papillomas when
given prior to TPA during promotion. In striking contrast to
the implications for a role of iNOS in carcinogenesis described
above, the same enzyme has been proposed to have an opposite
role in mouse skin carcinogenesis. Thus, Robertson et al. (35)
reported that levels of iNOS mRNA in dorsal skin isolated
from acetone-treated female SENCAR mice were substantially
higher than those observed in the cutaneous tissue of mice after
exposure to a single topical application of DMBA followed by
repetitive applications of TPA. Moreover, papillomas isolated
at 16 and 22 weeks of a tumor promotion protocol also had low
levels of iNOS mRNA. The diminished levels of iNOS mRNA
inversely correlated with the extent of TPA-induced epidermal
hyperplasia (35). Furthermore, treatment of DMBA-initiated
TPA-promoted mouse skin with a topical dose of nitroglycer-
ine, a NO generating vasodilator, increased the latency period
and reduced the tumor incidence and multiplicity (36).
Besides iNOS, COX-2 has also been reported to contribute
to tumor growth. Co-expression of iNOS and COX-2 has been
observed in malignancies (37). It was reported that enhanced
COX-2 expression is sufficient to induce mammary gland
tumorigenesis (38). The COX-2 transgenic mice were more
susceptible to skin carcinogenesis induced by DMBA than
wild-type mice (39). There is a causal relationship between
transgenic COX-2 expression in basal keratinocytes and epi-
dermal hyperplasia as well as dysplastic features at discrete
body sites (40). In contrast, COX-2 overexpression was found
to protect, rather than sensitize, transgenic mice against skin
tumor development induced by an initiation/promotion proto-
col (41). In our present study, inhibition of iNOS by AG
not only attenuated TPA-induced tumor promotion, but also
COX-2 expression in mouse skin, suggesting that the anti-
tumor promotional effect of AG may have resulted from
suppression of COX-2 expression as well as reduced NO
production. It would be worthwhile verifying the role of NO
in TPA-induced COX-2 induction by use of more selective
iNOS inhibitors, such as 1400W and GW274150.
Previous reports have indicated that iNOS can modulate
COX-2 activity or expression in cancer (42--44). Accumulated
data from both animal and cell culture studies have provided
evidence for interactions between the iNOS and COX-2 path-
ways. In the setting of inflammatory induction of iNOS and
COX-2, the majority of studies suggest that NO enhances
COX-2 expression and activity (24,45) and that this effect
may be cGMP dependent (27). In contrast, studies in LPS-
activated rat macrophages have suggested that NO may inhibit
A
B
Fig. 4. SNP-induced COX-2 expression visualized by immunohistochemical
staining. Skin samples were stained for COX-2 at the end of the study
protocol. Positive COX-2 staining yielded a brown colored product (arrow).
(A) Skin treated with acetone alone. (B) Skin treated with 20 mmol SNP for 2 h.
A color version of this figure is available as supplementary material online. Fig. 5. Effect of SNP on NF-kB activation and IkBa degradation in mouse
skin. (A) Dorsal skins of mice were treated topically with acetone alone or
0.5 or 20 mmol SNP. Mice were killed 1.5 h after the SNP treatment and
epidermal nuclear extracts were prepared and incubated with the radiolabeled
oligonucleotides containing the NF-kB consensus sequence for analysis by
EMSA. EMSA was performed in duplicate and showed similar patterns.
(B) Cytoplasmic extract from mouse skin treated with 20 mmol SNP for the
indicated time period was assayed for IkBa by western blot analysis.
(C) Female ICR mice were treated topically with acetone or with 40 mmol
PDTC and TPCK 30 min prior to 20 mmol SNP. Animals were killed by
cervical dislocation 2 h later. Expression of COX-2 was measured by western
blot analysis.
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both COX-2 induction and activity (46). In our study, expres-
sion of iNOS and COX-2 peaked at 2 and 4 h, respectively, in
TPA-treated mouse skin. Furthermore, the NOS inhibitor AG
suppressed TPA-induced COX-2 expression, suggesting that
expression of COX-2 can be regulated by NO in mouse skin.
However, the inhibition of COX-2 expression by AG was
partial. This appears to be due to the fact that AG cannot
block all the sources of NO production and also that NO is
not the only regulator of COX-2. A similar inhibitory effect
was attained with a more specific iNOS inhibitor, NAME.
Treatment of dorsal skin of female ICR mice with 2 or
20 mmol SNP significantly increased PGE2 synthesis, lending
further support to the possible role of NO in the induction of
COX-2 in mouse skin. In addition, SNP treatment resulted in
marked induction of COX-2 expression in mouse skin, which
was abolished by carboxy-PTIO, a known NO scavenger. SNP
can cause cytotoxicity because it releases ferricyanide. There-
fore, the right controls may be needed to verify that the
observed COX-2 inducing effect of SNP is due to NO, not to
the cyanide. To avoid such complication, we utilized another
NO donor, SNAP, that does not generate ferricyanide. We
confirmed that SNAP also increased expression of COX-2 in
mouse skin.
By interacting with superoxide, NO produces another reac-
tive nitrogen species, peroxynitrite. It has been reported that in
the macrophage cell line RAW 264.7, peroxynitrite, added
Fig. 6. Effect of SNP on NF-kB activation and COX-2 expression in keratinocytes. (A) Murine keratinocytes were stimulated with various concentrations of SNP
for 24 h and COX-2 protein levels were assayed by western blot analysis. (B) Murine keratinocytes were preincubated for 1 h with 25 mmol cell permeable
inhibitory peptide SN50 as well as a cell permeable control peptide SN50M and harvested 24 h after addition of SNP (0.5 mM). Quantification of COX-2
expression was normalized to actin using a densitometer. Values are means SD of three independent experiments. Significantly different from the group treated
with control (P 5 0.05). (C) Murine Pam212 keratinocytes were transiently transfected with a COX-2 promoter, a reporter vector and with pCMV-bgal
as an internal control for transfection. The COX-2 promoter activity was determined as described in Materials and methods. (D) pELAM-NF-kB and its basic
vector were transfected into murine keratinocytes. Eighteen hours after transfection, the cells were incubated with SNP for 6 h. The cells were lysed and assayed
for both luciferase and b-galactosidase activities. The results are presented as mean relative luciferase activities  SD (n  3), which was corrected for
transfection efficiency using b-galactosidase activity.
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directly to the medium, gradually released from 3-morpholi-
nosydnonimine (SIN-1) or generated in situ from the NO
donor SNAP with a superoxide generating system (xanthine/
xanthine oxidase), significantly activated COX-2 and also
prostanoid production (47). Although there are numerous
reports addressing the possible cross-talk between iNOS and
COX-2, it has been proposed that NO simply acts as a pre-
cursor to peroxynitrite that is able to activate COX-2 to synthe-
size prostaglandins (48). Marnett et al. have provided
compelling evidence that a targeted deletion of the iNOS
gene with a resultant reduction in NO or NO-derived molecu-
lar species, including peroxynitrite, leads to a significant
decrease in the formation of prostaglandins (49). We have
reported that topical application of the peroxynitrite releasing
compound SIN-1 leads to dose-related increases in the expres-
sion of COX-2 in mouse skin (50). These findings, taken
together, suggest that peroxynitrite may play an important
role in prostaglandin biosynthesis and inflammation.
The eukaryotic transcription factor NF-kB plays a central
role in inflammatory as well as immune responses. The 50-
flanking region of cox-2 contains NF-kB-binding sites (51).
In line with this notion, NF-kB has been shown to be a critical
regulator of COX-2 expression in many cell lines (52,53).
Recent findings have suggested that NF-kB is a potential
molecular target for the biological actions of NO. Neverthe-
less, the effects of NO on NF-kB are quite controversial. In
fact, NO can activate NF-kB DNA binding activity in some
cell types (54,55) while it exerts an inhibitory effect in others
(56,57). Previous in vitro and cell line studies have shown that
S-nitrosylation of the p50 subunit can inhibit DNA binding of
NF-kB (58--60). Modification of NF-kB by NO may serve as a
negative feedback mechanism that regulates COX-2 transcrip-
tion. Thus, a negative feedback loop may exist, which couples
increased NO production to decreased transcription of the
cox-2 gene. SNP, when applied onto dorsal skin of mice, caused
NF-kB activation through degradation of IkBa. According to
our previous study, topical application of PDTC, a known
inhibitor of NF-kB, resulted in a dose-related suppression of
TPA-induced activation of NF-kB and also caused reduced
COX-2 protein expression in mouse skin (50). To verify the
role of NF-kB in induction of COX-2 expression mediated by
the NO pathway in mouse skin, we have examined the effect of
two different NF-kB inhibitors (PDTC and TPCK) on SNP-
induced COX-2 expression. Both NF-kB inhibitors suppressed
the induction of COX-2 expression by SNP. We also con-
firmed the inhibitory effect of SN50, a cell permeable inhibi-
tory peptide of NF-kB translocation, on COX-2 expression in
keratinocytes. These data further support the notion that the
NO could induce COX-2 expression in mouse skin through
NF-kB activation.
Regardless of the animal species, promoter regions of the
cox-2 genes contain a canonical TATA box and various puta-
tive transcriptional regulatory elements, such as CRE, NF-IL6,
AP-2 and SP-1, in addition to the NF-kB site (51). Among
these elements, CRE (61) and NF-IL6 (62) have been shown to
act as positive regulatory elements for COX-2 transcription.
Therefore, the possibility of cox-2 gene transcription regulated
by transcription factors other than NF-kB cannot be excluded.
Additional studies using COX-2 promoters with mutated or
deleted sequences for binding to a specific transcription factor
will clarify which transcription factor(s) plays a prime role in
NO-mediated COX-2 induction in murine keratinocytes.
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